drugset / Trial / NCT00108121
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine whether topical application of PEP005 is safe for the treatment of nodular basal cell carcinoma.
Timeline
- Start
- 2005-03
- Primary completion
- 2006-05
- Completion
- 2006-05
Publications
- Results Rosen RH, Katsamas J, Ogbourne SM, Welburn P. Early phase clinical development of PEP005 topical gel for basal cell carcinoma. 21st World Congress of Dermatology, Buenos Aires, 2007. 2007: Poster no. P5755 (1 p.)
- Results Rosen RH, Freeman M, Siller G, Katsamas J, Ogbourne SM. Safety and efficacy of PEP005 Topical Gel for the treatment of nodular and superficial forms of basal cell carcinoma. Summer Academy, American Academy of Dermatology meeting, New York, NY, 2007. 2007: Poster no. P1502
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ingenol mebutate | Small molecule | 0.0025 % | Topical |
| Subject | ingenol mebutate | Small molecule | 0.01 % | Topical |
| Subject | ingenol mebutate | Small molecule | 0.05 % | Topical |